{"transactions":[{"id":828920,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":25480,"kind":"person","name":"Lazar David E.","position":1,"cik":"0001932843","reported_name":"Lazar David E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series AAA Convertible Non-Redeemable Preferred Stock","published_at":"2026-03-24T20:02:56.000Z","date":"2026-03-23","kind":"sale","planned":false,"acquired":false,"shares":700000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 19, 2026, David E. Lazar (the \"Reporting Person\") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the \"March 2026 Transaction\"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series AAA Preferred Stock is convertible at the option of the holder for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 19, 2026, David E. Lazar (the \"Reporting Person\") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the \"March 2026 Transaction\"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series AAA Preferred Stock is perpetual and therefore has no expiration date."}],"balance_after":0,"derivative":{"exercise_date":"2026-03-20","underlying":"Common Stock","underlying_shares":105000000},"source":{"system":"sec-edgar","filing":"0000921895-26-000788","document":"form412227indp_03232026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000092189526000788/form412227indp_03232026.xml","form_type":"4"}},{"id":828919,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":25480,"kind":"person","name":"Lazar David E.","position":1,"cik":"0001932843","reported_name":"Lazar David E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series AA Convertible Non-Redeemable Preferred Stock","published_at":"2026-03-24T20:02:56.000Z","date":"2026-03-23","kind":"sale","planned":false,"acquired":false,"shares":196800,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 19, 2026, David E. Lazar (the \"Reporting Person\") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the \"March 2026 Transaction\"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series AA Preferred Stock is convertible at the option of the holder for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 19, 2026, David E. Lazar (the \"Reporting Person\") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the \"March 2026 Transaction\"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series AA Preferred Stock is perpetual and therefore has no expiration date."}],"balance_after":103200,"derivative":{"exercise_date":"2026-03-20","underlying":"Common Stock","underlying_shares":3936000},"source":{"system":"sec-edgar","filing":"0000921895-26-000788","document":"form412227indp_03232026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000092189526000788/form412227indp_03232026.xml","form_type":"4"}},{"id":876482,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":64216,"kind":"person","name":"Jabbour Jerome D","position":1,"cik":"0001698838","reported_name":"Jabbour Jerome D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy Common Stock","published_at":"2026-02-27T16:06:16.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.06,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-008330","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698838/000149315226008330/ownership.xml","form_type":"4"}},{"id":904814,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Warrants (right to buy)","published_at":"2026-02-13T21:15:18.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":12136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged."}],"balance_after":12136,"derivative":{"exercise_price":1.75,"exercise_date":"2026-02-11","expiration_date":"2030-07-27","underlying":"Common Stock","underlying_shares":12136},"source":{"system":"sec-edgar","filing":"0001493152-26-006707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315226006707/ownership.xml","form_type":"4"}},{"id":904813,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Warrants (right to buy)","published_at":"2026-02-13T21:15:18.000Z","date":"2026-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged."}],"balance_after":0,"derivative":{"exercise_price":8.3,"exercise_date":"2025-07-27","expiration_date":"2030-07-27","underlying":"Common Stock","underlying_shares":12136},"source":{"system":"sec-edgar","filing":"0001493152-26-006707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315226006707/ownership.xml","form_type":"4"}},{"id":904812,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Warrants (right to buy)","published_at":"2026-02-13T21:15:18.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":1519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged."}],"balance_after":1519,"derivative":{"exercise_price":1.75,"exercise_date":"2026-02-11","expiration_date":"2029-11-25","underlying":"Common Stock","underlying_shares":1519},"source":{"system":"sec-edgar","filing":"0001493152-26-006707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315226006707/ownership.xml","form_type":"4"}},{"id":904811,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Warrants (right to buy)","published_at":"2026-02-13T21:15:18.000Z","date":"2026-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged."}],"balance_after":0,"derivative":{"exercise_price":29.4,"exercise_date":"2024-11-25","expiration_date":"2029-11-25","underlying":"Common Stock","underlying_shares":1519},"source":{"system":"sec-edgar","filing":"0001493152-26-006707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315226006707/ownership.xml","form_type":"4"}},{"id":904810,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Warrants (right to buy)","published_at":"2026-02-13T21:15:18.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":3033,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged."}],"balance_after":3033,"derivative":{"exercise_price":1.75,"exercise_date":"2026-02-11","expiration_date":"2029-08-08","underlying":"Common Stock","underlying_shares":3033},"source":{"system":"sec-edgar","filing":"0001493152-26-006707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315226006707/ownership.xml","form_type":"4"}},{"id":904809,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Warrants (right to buy)","published_at":"2026-02-13T21:15:18.000Z","date":"2026-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3033,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged."}],"balance_after":0,"derivative":{"exercise_price":47.6,"exercise_date":"2024-08-08","expiration_date":"2029-08-08","underlying":"Common Stock","underlying_shares":3033},"source":{"system":"sec-edgar","filing":"0001493152-26-006707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315226006707/ownership.xml","form_type":"4"}},{"id":933500,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":25914,"kind":"person","name":"Ben-Tzvi Avraham","position":1,"cik":"0001944721","reported_name":"Ben-Tzvi Avraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy Common Stock","published_at":"2026-01-23T02:57:06.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.95,"expiration_date":"2035-12-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-003293","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1944721/000149315226003293/ownership.xml","form_type":"4"}},{"id":933499,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":25914,"kind":"person","name":"Ben-Tzvi Avraham","position":1,"cik":"0001944721","reported_name":"Ben-Tzvi Avraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T02:57:06.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person acquired 25,000 shares of restricted common stock of the Issuer pursuant to a consulting agreement dated January 20, 2026, which shares vested 100% upon grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 100 shares of common stock of the Issuer held in a Roth IRA."}],"balance_after":25100,"source":{"system":"sec-edgar","filing":"0001493152-26-003293","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1944721/000149315226003293/ownership.xml","form_type":"4"}},{"id":933279,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":24574,"kind":"person","name":"NATAN DAVID","position":1,"cik":"0001253108","reported_name":"NATAN DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy Common Stock","published_at":"2026-01-23T02:56:24.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.69,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-003292","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253108/000149315226003292/ownership.xml","form_type":"4"}},{"id":957978,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-29T21:01:21.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":216617,"price":2.03,"value":439732.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person acquired 216,617 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025."}],"balance_after":229929,"source":{"system":"sec-edgar","filing":"0001493152-25-029355","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315225029355/ownership.xml","form_type":"4"}},{"id":957856,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-29T16:01:23.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":26758,"price":2.03,"value":54318.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person acquired 26,758 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025."}],"balance_after":26758,"source":{"system":"sec-edgar","filing":"0001493152-25-029356","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000149315225029356/ownership.xml","form_type":"4"}},{"id":958326,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70836,"kind":"person","name":"Newman Michael James","position":1,"cik":"0001876315","reported_name":"Newman Michael James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO and Director"}}],"security":"Common Stock","published_at":"2025-12-29T16:01:19.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":52204,"price":2.03,"value":105974.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person acquired 52,204 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025."}],"balance_after":101074,"source":{"system":"sec-edgar","filing":"0001493152-25-029354","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1876315/000149315225029354/ownership.xml","form_type":"4"}},{"id":957884,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-12-29T16:01:18.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":54421,"price":2.03,"value":110474.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person acquired 54,421 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025."}],"balance_after":54426,"source":{"system":"sec-edgar","filing":"0001493152-25-029353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000149315225029353/ownership.xml","form_type":"4"}},{"id":1079654,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock Warrants","published_at":"2025-07-29T20:15:27.000Z","date":"2025-07-27","kind":"grant","planned":false,"acquired":true,"shares":12136,"price":8.3024,"value":100757.9264,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025."}],"balance_after":16688,"derivative":{"exercise_price":8.3024,"exercise_date":"2025-07-27","expiration_date":"2030-07-27","underlying":"Common Stock","underlying_shares":12136},"source":{"system":"sec-edgar","filing":"0001641172-25-021376","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000164117225021376/ownership.xml","form_type":"4"}},{"id":1079653,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-29T20:15:27.000Z","date":"2025-07-27","kind":"grant","planned":false,"acquired":true,"shares":6068,"price":8.3024,"value":50378.9632,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025."}],"balance_after":13312,"source":{"system":"sec-edgar","filing":"0001641172-25-021376","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000164117225021376/ownership.xml","form_type":"4"}},{"id":1114715,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":42337,"kind":"person","name":"Hayes William B","position":1,"cik":"0001320940","reported_name":"Hayes William B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T20:05:15.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 10, 2026."}],"balance_after":12500,"derivative":{"exercise_price":0.33,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001641172-25-014691","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320940/000164117225014691/ownership.xml","form_type":"4"}},{"id":1114572,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T20:05:13.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 10, 2026."}],"balance_after":30000,"derivative":{"exercise_price":0.33,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001641172-25-014695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000164117225014695/ownership.xml","form_type":"4"}},{"id":1114502,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":78614,"kind":"person","name":"Gilbert Mark John","position":1,"cik":"0001897698","reported_name":"Gilbert Mark John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T20:05:11.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 10, 2026."}],"balance_after":12500,"derivative":{"exercise_price":0.33,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001641172-25-014690","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000164117225014690/ownership.xml","form_type":"4"}},{"id":1114925,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":75373,"kind":"person","name":"Karah Hila","position":1,"cik":"0001668116","reported_name":"Karah Hila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T16:05:18.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 10, 2026."}],"balance_after":12500,"derivative":{"exercise_price":0.33,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001641172-25-014692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668116/000164117225014692/ownership.xml","form_type":"4"}},{"id":1114645,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":78620,"kind":"person","name":"Martell Robert","position":1,"cik":"0001529922","reported_name":"Martell Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T16:05:17.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 10, 2026."}],"balance_after":12500,"derivative":{"exercise_price":0.33,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001641172-25-014694","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529922/000164117225014694/ownership.xml","form_type":"4"}},{"id":1114610,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":16235,"kind":"person","name":"MADDALUNA ANTHONY J","position":1,"cik":"0001566333","reported_name":"MADDALUNA ANTHONY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T16:05:14.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 10, 2026."}],"balance_after":12500,"derivative":{"exercise_price":0.33,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001641172-25-014693","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566333/000164117225014693/ownership.xml","form_type":"4"}},{"id":1173133,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:22.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.5,"value":125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":355.2,"exercise_date":"2018-06-28","expiration_date":"2025-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003825","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000164117225003825/ownership.xml","form_type":"4"}},{"id":1173132,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:22.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.5,"value":125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":388.64,"exercise_date":"2019-06-28","expiration_date":"2026-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003825","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000164117225003825/ownership.xml","form_type":"4"}},{"id":1173131,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:22.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500,"price":0.5,"value":250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":24.6,"exercise_date":"2020-07-15","expiration_date":"2027-07-15","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001641172-25-003825","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000164117225003825/ownership.xml","form_type":"4"}},{"id":1173186,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:21.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"price":0.037,"value":46.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":355.2,"exercise_date":"2018-06-28","expiration_date":"2025-06-28","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001641172-25-003824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000164117225003824/ownership.xml","form_type":"4"}},{"id":1173185,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:21.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1563,"price":0.037,"value":57.831,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":611.2,"exercise_date":"2019-04-04","expiration_date":"2026-04-04","underlying":"Common Stock","underlying_shares":1563},"source":{"system":"sec-edgar","filing":"0001641172-25-003824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000164117225003824/ownership.xml","form_type":"4"}},{"id":1173184,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"sStock Option (right to buy)","published_at":"2025-04-11T20:15:21.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1500,"price":0.037,"value":55.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":425.6,"exercise_date":"2017-04-10","expiration_date":"2027-04-10","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001641172-25-003824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000164117225003824/ownership.xml","form_type":"4"}},{"id":1173183,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:21.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":813,"price":0.037,"value":30.081,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":425.6,"exercise_date":"2017-05-01","expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":813},"source":{"system":"sec-edgar","filing":"0001641172-25-003824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000164117225003824/ownership.xml","form_type":"4"}},{"id":1173182,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:21.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3750,"price":0.037,"value":138.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":24.6,"exercise_date":"2020-07-15","expiration_date":"2027-07-15","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001641172-25-003824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000164117225003824/ownership.xml","form_type":"4"}},{"id":1173181,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:21.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4750,"price":0.037,"value":175.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":536,"exercise_date":"2017-12-11","expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001641172-25-003824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000164117225003824/ownership.xml","form_type":"4"}},{"id":1173214,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":42337,"kind":"person","name":"Hayes William B","position":1,"cik":"0001320940","reported_name":"Hayes William B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:16.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.5,"value":125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":355.2,"exercise_date":"2018-06-28","expiration_date":"2025-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1320940/000164117225003820/ownership.xml","form_type":"4"}},{"id":1173213,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":42337,"kind":"person","name":"Hayes William B","position":1,"cik":"0001320940","reported_name":"Hayes William B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:16.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.5,"value":125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":388.64,"exercise_date":"2019-06-28","expiration_date":"2026-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1320940/000164117225003820/ownership.xml","form_type":"4"}},{"id":1173212,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":42337,"kind":"person","name":"Hayes William B","position":1,"cik":"0001320940","reported_name":"Hayes William B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:16.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500,"price":0.5,"value":250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":24.6,"exercise_date":"2020-07-15","expiration_date":"2027-07-15","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001641172-25-003820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320940/000164117225003820/ownership.xml","form_type":"4"}},{"id":1173105,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:25.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1125,"price":0.071,"value":79.875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":610.24,"exercise_date":"2019-01-22","expiration_date":"2026-01-22","underlying":"Common Stock","underlying_shares":1125},"source":{"system":"sec-edgar","filing":"0001641172-25-003826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000164117225003826/ownership.xml","form_type":"4"}},{"id":1173104,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:25.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41,"price":0.071,"value":2.911,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":331.2,"exercise_date":"2016-03-27","expiration_date":"2026-03-27","underlying":"Common Stock","underlying_shares":41},"source":{"system":"sec-edgar","filing":"0001641172-25-003826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000164117225003826/ownership.xml","form_type":"4"}},{"id":1173103,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:25.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500,"price":0.071,"value":35.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":357.28,"exercise_date":"2016-07-25","expiration_date":"2026-07-25","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001641172-25-003826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000164117225003826/ownership.xml","form_type":"4"}},{"id":1173102,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:25.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500,"price":0.071,"value":35.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":357.28,"exercise_date":"2016-07-25","expiration_date":"2026-07-25","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001641172-25-003826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000164117225003826/ownership.xml","form_type":"4"}},{"id":1173101,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:25.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"price":0.071,"value":177.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":72,"exercise_date":"2019-09-13","expiration_date":"2026-09-13","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001641172-25-003826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000164117225003826/ownership.xml","form_type":"4"}},{"id":1173100,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:25.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1125,"price":0.071,"value":79.875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":34.32,"exercise_date":"2020-02-17","expiration_date":"2027-02-17","underlying":"Common Stock","underlying_shares":1125},"source":{"system":"sec-edgar","filing":"0001641172-25-003826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000164117225003826/ownership.xml","form_type":"4"}},{"id":1173099,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:25.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"price":0.071,"value":88.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":25.72,"exercise_date":"2020-09-16","expiration_date":"2027-09-16","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001641172-25-003826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000164117225003826/ownership.xml","form_type":"4"}},{"id":1173130,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:24.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1125,"price":0.059,"value":66.375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":610.24,"exercise_date":"2019-01-22","expiration_date":"2026-01-22","underlying":"Common Stock","underlying_shares":1125},"source":{"system":"sec-edgar","filing":"0001641172-25-003822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000164117225003822/ownership.xml","form_type":"4"}},{"id":1173129,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:24.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"price":0.059,"value":147.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":72,"exercise_date":"2019-09-13","expiration_date":"2026-09-13","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001641172-25-003822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000164117225003822/ownership.xml","form_type":"4"}},{"id":1173128,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:24.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1125,"price":0.059,"value":66.375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":34.32,"exercise_date":"2020-02-17","expiration_date":"2027-02-17","underlying":"Common Stock","underlying_shares":1125},"source":{"system":"sec-edgar","filing":"0001641172-25-003822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000164117225003822/ownership.xml","form_type":"4"}},{"id":1173127,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:24.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"price":0.059,"value":73.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":25.72,"exercise_date":"2020-09-16","expiration_date":"2027-09-16","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001641172-25-003822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000164117225003822/ownership.xml","form_type":"4"}},{"id":1173126,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:24.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":750,"price":0.059,"value":44.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":684.8,"exercise_date":"2017-10-23","expiration_date":"2027-10-23","underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001641172-25-003822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000164117225003822/ownership.xml","form_type":"4"}},{"id":1173125,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:24.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1750,"price":0.059,"value":103.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":684.8,"exercise_date":"2017-12-11","expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001641172-25-003822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000164117225003822/ownership.xml","form_type":"4"}},{"id":1173153,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":16235,"kind":"person","name":"MADDALUNA ANTHONY J","position":1,"cik":"0001566333","reported_name":"MADDALUNA ANTHONY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:19.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.5,"value":125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":355.2,"exercise_date":"2018-06-28","expiration_date":"2025-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566333/000164117225003823/ownership.xml","form_type":"4"}},{"id":1173152,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":16235,"kind":"person","name":"MADDALUNA ANTHONY J","position":1,"cik":"0001566333","reported_name":"MADDALUNA ANTHONY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:19.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.5,"value":125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":388.64,"exercise_date":"2019-06-28","expiration_date":"2026-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566333/000164117225003823/ownership.xml","form_type":"4"}},{"id":1173151,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":16235,"kind":"person","name":"MADDALUNA ANTHONY J","position":1,"cik":"0001566333","reported_name":"MADDALUNA ANTHONY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:19.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500,"price":0.5,"value":250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":24.6,"exercise_date":"2020-07-15","expiration_date":"2027-07-15","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001641172-25-003823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566333/000164117225003823/ownership.xml","form_type":"4"}},{"id":1173287,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":75373,"kind":"person","name":"Karah Hila","position":1,"cik":"0001668116","reported_name":"Karah Hila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:17.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.39,"value":97.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":355.2,"exercise_date":"2018-06-28","expiration_date":"2025-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003821","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668116/000164117225003821/ownership.xml","form_type":"4"}},{"id":1173286,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":75373,"kind":"person","name":"Karah Hila","position":1,"cik":"0001668116","reported_name":"Karah Hila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:17.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":281,"price":0.39,"value":109.59,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":480,"exercise_date":"2016-05-22","expiration_date":"2026-05-22","underlying":"Common Stock","underlying_shares":281},"source":{"system":"sec-edgar","filing":"0001641172-25-003821","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668116/000164117225003821/ownership.xml","form_type":"4"}},{"id":1173285,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":75373,"kind":"person","name":"Karah Hila","position":1,"cik":"0001668116","reported_name":"Karah Hila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:17.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.39,"value":97.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":388.64,"exercise_date":"2019-06-28","expiration_date":"2026-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003821","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668116/000164117225003821/ownership.xml","form_type":"4"}},{"id":1173284,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":75373,"kind":"person","name":"Karah Hila","position":1,"cik":"0001668116","reported_name":"Karah Hila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:15:17.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500,"price":0.39,"value":195.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":24.6,"exercise_date":"2020-07-15","expiration_date":"2027-07-15","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001641172-25-003821","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668116/000164117225003821/ownership.xml","form_type":"4"}},{"id":1350668,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common Stock Warrants","published_at":"2024-11-26T21:12:39.000Z","date":"2024-11-25","kind":"grant","planned":false,"acquired":true,"shares":42553,"price":1.175,"value":49999.775,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person acquired 42,553 shares of common stock and 42,553 warrants to purchase common stock from the Issuer for an aggregate purchase price of $49,999.78."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person acquired 42,553 shares of common stock and 42,553 warrants to purchase common stock from the Issuer for an aggregate purchase price of $49,999.78."}],"balance_after":42553,"derivative":{"exercise_price":1.05,"expiration_date":"2029-11-25","underlying":"Common Stock","underlying_shares":42553},"source":{"system":"sec-edgar","filing":"0001493152-24-047808","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315224047808/ownership.xml","form_type":"4"}},{"id":1350667,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common stock","published_at":"2024-11-26T21:12:39.000Z","date":"2024-11-25","kind":"grant","planned":false,"acquired":true,"shares":42553,"price":1.175,"value":49999.775,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person acquired 42,553 shares of common stock and 42,553 warrants to purchase common stock from the Issuer for an aggregate purchase price of $49,999.78."}],"balance_after":202859,"source":{"system":"sec-edgar","filing":"0001493152-24-047808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315224047808/ownership.xml","form_type":"4"}},{"id":1388029,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-10T20:05:09.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.105,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001493152-24-040726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315224040726/ownership.xml","form_type":"4"}},{"id":1388178,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70836,"kind":"person","name":"Newman Michael James","position":1,"cik":"0001876315","reported_name":"Newman Michael James","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CSO and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-10T16:05:15.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.105,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001493152-24-040730","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1876315/000149315224040730/ownership.xml","form_type":"4"}},{"id":1387971,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-10T16:05:13.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.105,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001493152-24-040729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000149315224040729/ownership.xml","form_type":"4"}},{"id":1387977,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":86814,"kind":"person","name":"Waltzman Roger J.","position":1,"cik":"0001678987","reported_name":"Waltzman Roger J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-10T16:05:12.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.105,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001493152-24-040728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678987/000149315224040728/ownership.xml","form_type":"4"}},{"id":1387979,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-10T16:05:10.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.105,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001493152-24-040727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000149315224040727/ownership.xml","form_type":"4"}},{"id":1437729,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common Stock Warrants","published_at":"2024-08-08T21:30:46.000Z","date":"2024-08-08","kind":"grant","planned":false,"acquired":true,"shares":84932,"price":1.825,"value":155000.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person acquired 84,932 shares of common stock and 84,932 warrants to purchase common stock from the Issuer for an aggregate purchase price of $155,000.90."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person acquired 84,932 shares of common stock and 84,932 warrants to purchase common stock from the Issuer for an aggregate purchase price of $155,000.90."}],"balance_after":84932,"derivative":{"exercise_price":1.7,"expiration_date":"2029-08-08","underlying":"Common Stock","underlying_shares":84932},"source":{"system":"sec-edgar","filing":"0001493152-24-030839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315224030839/ownership.xml","form_type":"4"}},{"id":1437728,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common stock","published_at":"2024-08-08T21:30:46.000Z","date":"2024-08-08","kind":"grant","planned":false,"acquired":true,"shares":84932,"price":1.825,"value":155000.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person acquired 84,932 shares of common stock and 84,932 warrants to purchase common stock from the Issuer for an aggregate purchase price of $155,000.90."}],"balance_after":160306,"source":{"system":"sec-edgar","filing":"0001493152-24-030839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315224030839/ownership.xml","form_type":"4"}},{"id":1485958,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":78614,"kind":"person","name":"Gilbert Mark John","position":1,"cik":"0001897698","reported_name":"Gilbert Mark John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T21:00:16.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 6, 2025."}],"balance_after":12500,"derivative":{"exercise_price":2.63,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-24-023147","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224023147/ownership.xml","form_type":"4"}},{"id":1486122,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T21:00:14.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 6, 2025."}],"balance_after":30000,"derivative":{"exercise_price":2.63,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-24-023149","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000149315224023149/ownership.xml","form_type":"4"}},{"id":1486346,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":42337,"kind":"person","name":"Hayes William B","position":1,"cik":"0001320940","reported_name":"Hayes William B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T21:00:09.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 6, 2025."}],"balance_after":12500,"derivative":{"exercise_price":2.63,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-24-023151","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320940/000149315224023151/ownership.xml","form_type":"4"}},{"id":1486787,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":75373,"kind":"person","name":"Karah Hila","position":1,"cik":"0001668116","reported_name":"Karah Hila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T17:00:17.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 6, 2025."}],"balance_after":12500,"derivative":{"exercise_price":2.63,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-24-023152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668116/000149315224023152/ownership.xml","form_type":"4"}},{"id":1486172,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":16235,"kind":"person","name":"MADDALUNA ANTHONY J","position":1,"cik":"0001566333","reported_name":"MADDALUNA ANTHONY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T17:00:12.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 6, 2025."}],"balance_after":12500,"derivative":{"exercise_price":2.63,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-24-023148","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566333/000149315224023148/ownership.xml","form_type":"4"}},{"id":1486228,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":78620,"kind":"person","name":"Martell Robert","position":1,"cik":"0001529922","reported_name":"Martell Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T17:00:11.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 6, 2025."}],"balance_after":12500,"derivative":{"exercise_price":2.63,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-24-023150","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529922/000149315224023150/ownership.xml","form_type":"4"}},{"id":1672752,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-23T21:15:44.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2025 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 22, 2027."}],"balance_after":100000,"derivative":{"exercise_price":1.74,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-24-003450","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315224003450/ownership.xml","form_type":"4"}},{"id":1672649,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-23T16:15:56.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2025 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 22, 2027."}],"balance_after":75000,"derivative":{"exercise_price":1.74,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001493152-24-003451","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000149315224003451/ownership.xml","form_type":"4"}},{"id":1672646,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":86814,"kind":"person","name":"Waltzman Roger J.","position":1,"cik":"0001678987","reported_name":"Waltzman Roger J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-23T16:15:55.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2025 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 22, 2027."}],"balance_after":75000,"derivative":{"exercise_price":1.74,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001493152-24-003449","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678987/000149315224003449/ownership.xml","form_type":"4"}},{"id":1672645,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-23T16:15:47.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2025 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 22, 2027."}],"balance_after":40000,"derivative":{"exercise_price":1.74,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-24-003445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000149315224003445/ownership.xml","form_type":"4"}},{"id":1673211,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70836,"kind":"person","name":"Newman Michael James","position":1,"cik":"0001876315","reported_name":"Newman Michael James","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CSO and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-23T16:15:43.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":43250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2025 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 22, 2027."}],"balance_after":43250,"derivative":{"exercise_price":1.74,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":43250},"source":{"system":"sec-edgar","filing":"0001493152-24-003447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1876315/000149315224003447/ownership.xml","form_type":"4"}},{"id":1806110,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":110501,"kind":"person","name":"Anderson Glen R.","position":1,"cik":"0001878961","reported_name":"Anderson Glen R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-16T18:01:31.000Z","date":"2023-08-14","kind":"purchase","planned":false,"acquired":true,"shares":23934,"price":2.34,"value":56005.56,"ownership":{"direct":false,"nature":"By Anderson Family Trust u/a dtd 01/07/2018"},"balance_after":1190400,"source":{"system":"sec-edgar","filing":"0001493152-23-029212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878961/000149315223029212/ownership.xml","form_type":"4"}},{"id":1806109,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":110501,"kind":"person","name":"Anderson Glen R.","position":1,"cik":"0001878961","reported_name":"Anderson Glen R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-16T18:01:31.000Z","date":"2023-08-11","kind":"purchase","planned":false,"acquired":true,"shares":35064,"price":2.12,"value":74335.68,"ownership":{"direct":false,"nature":"By Anderson Family Trust u/a dtd 01/07/2018"},"balance_after":1166466,"source":{"system":"sec-edgar","filing":"0001493152-23-029212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878961/000149315223029212/ownership.xml","form_type":"4"}},{"id":1806108,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":110501,"kind":"person","name":"Anderson Glen R.","position":1,"cik":"0001878961","reported_name":"Anderson Glen R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-16T18:01:31.000Z","date":"2023-08-10","kind":"purchase","planned":false,"acquired":true,"shares":44354,"price":1.94,"value":86046.76,"ownership":{"direct":false,"nature":"By Anderson Family Trust u/a dtd 01/07/2018"},"balance_after":1131402,"source":{"system":"sec-edgar","filing":"0001493152-23-029212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878961/000149315223029212/ownership.xml","form_type":"4"}},{"id":1813594,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":86814,"kind":"person","name":"Waltzman Roger J.","position":1,"cik":"0001678987","reported_name":"Waltzman Roger J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-07T17:25:41.000Z","date":"2023-08-07","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on August 7, 2024 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on August 7, 2026."}],"balance_after":90000,"derivative":{"exercise_price":1.85,"expiration_date":"2033-08-07","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001493152-23-027061","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678987/000149315223027061/ownership.xml","form_type":"4"}},{"id":1874449,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":42337,"kind":"person","name":"Hayes William B","position":1,"cik":"0001320940","reported_name":"Hayes William B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T20:15:46.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on May 25, 2024."}],"balance_after":12500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-23-019463","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320940/000149315223019463/ownership.xml","form_type":"4"}},{"id":1874139,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":78614,"kind":"person","name":"Gilbert Mark John","position":1,"cik":"0001897698","reported_name":"Gilbert Mark John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T20:15:42.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on May 25, 2024."}],"balance_after":12500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-23-019461","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223019461/ownership.xml","form_type":"4"}},{"id":1874230,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T20:15:38.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on May 25, 2024."}],"balance_after":30000,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-23-019460","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000149315223019460/ownership.xml","form_type":"4"}},{"id":1874850,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":75373,"kind":"person","name":"Karah Hila","position":1,"cik":"0001668116","reported_name":"Karah Hila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T16:15:50.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on May 25, 2024."}],"balance_after":12500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-23-019462","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668116/000149315223019462/ownership.xml","form_type":"4"}},{"id":1874257,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":16235,"kind":"person","name":"MADDALUNA ANTHONY J","position":1,"cik":"0001566333","reported_name":"MADDALUNA ANTHONY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T16:15:26.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on May 25, 2024."}],"balance_after":12500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-23-019459","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566333/000149315223019459/ownership.xml","form_type":"4"}},{"id":2015317,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":78620,"kind":"person","name":"Martell Robert","position":1,"cik":"0001529922","reported_name":"Martell Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-14T17:58:30.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on February 13, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.71,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-23-005058","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529922/000149315223005058/ownership.xml","form_type":"4"}},{"id":2049433,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-20T21:05:55.000Z","date":"2023-01-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on January 18, 2024 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 18, 2026."}],"balance_after":100000,"derivative":{"exercise_price":1.61,"expiration_date":"2033-01-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-23-002021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315223002021/ownership.xml","form_type":"4"}},{"id":2049382,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70808,"kind":"person","name":"Linscott Walt Addison","position":1,"cik":"0001648585","reported_name":"Linscott Walt Addison","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-20T16:05:51.000Z","date":"2023-01-18","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on January 18, 2024 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 18, 2026."}],"balance_after":40000,"derivative":{"exercise_price":1.61,"expiration_date":"2033-01-18","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-23-002023","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1648585/000149315223002023/ownership.xml","form_type":"4"}},{"id":2049354,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70804,"kind":"person","name":"Sassi Nir","position":1,"cik":"0001760673","reported_name":"Sassi Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-20T16:05:47.000Z","date":"2023-01-18","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on January 18, 2024 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 18, 2026."}],"balance_after":40000,"derivative":{"exercise_price":1.61,"expiration_date":"2033-01-18","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-23-002020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760673/000149315223002020/ownership.xml","form_type":"4"}},{"id":2049873,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":70836,"kind":"person","name":"Newman Michael James","position":1,"cik":"0001876315","reported_name":"Newman Michael James","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CSO and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-20T16:05:43.000Z","date":"2023-01-18","kind":"grant","acquired":true,"shares":43250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on January 18, 2024 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 18, 2026."}],"balance_after":43250,"derivative":{"exercise_price":1.61,"expiration_date":"2033-01-18","underlying":"Common Stock","underlying_shares":43250},"source":{"system":"sec-edgar","filing":"0001493152-23-002019","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1876315/000149315223002019/ownership.xml","form_type":"4"}},{"id":2080868,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":121450,"kind":"person","name":"Litchev Boyan Vesselinov","position":1,"cik":"0001902726","reported_name":"Litchev Boyan Vesselinov","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-12-20T02:06:32.000Z","date":"2022-12-01","kind":"purchase","acquired":true,"shares":500,"price":1.8709,"value":935.45,"ownership":{"direct":true},"balance_after":1150,"source":{"system":"sec-edgar","filing":"0001493152-22-035926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222035926/ownership.xml","form_type":"4"}},{"id":2080867,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":121450,"kind":"person","name":"Litchev Boyan Vesselinov","position":1,"cik":"0001902726","reported_name":"Litchev Boyan Vesselinov","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-12-20T02:06:32.000Z","date":"2022-11-22","kind":"purchase","acquired":true,"shares":500,"price":1.83,"value":915.0,"ownership":{"direct":true},"balance_after":650,"source":{"system":"sec-edgar","filing":"0001493152-22-035926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222035926/ownership.xml","form_type":"4"}},{"id":2080866,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":121450,"kind":"person","name":"Litchev Boyan Vesselinov","position":1,"cik":"0001902726","reported_name":"Litchev Boyan Vesselinov","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-12-20T02:06:32.000Z","date":"2022-03-02","kind":"purchase","acquired":true,"shares":50,"price":4.0926,"value":204.63,"ownership":{"direct":true},"balance_after":150,"source":{"system":"sec-edgar","filing":"0001493152-22-035926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222035926/ownership.xml","form_type":"4"}},{"id":2080865,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":121450,"kind":"person","name":"Litchev Boyan Vesselinov","position":1,"cik":"0001902726","reported_name":"Litchev Boyan Vesselinov","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-12-20T02:06:32.000Z","date":"2022-01-31","kind":"purchase","acquired":true,"shares":100,"price":4.65,"value":465.0,"ownership":{"direct":true},"balance_after":100,"source":{"system":"sec-edgar","filing":"0001493152-22-035926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222035926/ownership.xml","form_type":"4"}},{"id":2106572,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common stock","published_at":"2022-11-22T13:00:13.000Z","date":"2022-11-21","kind":"purchase","acquired":true,"shares":9600,"price":1.9,"value":18240.0,"ownership":{"direct":true},"balance_after":75374,"source":{"system":"sec-edgar","filing":"0001493152-22-033241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315222033241/ownership.xml","form_type":"4"}},{"id":2106571,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common stock","published_at":"2022-11-22T13:00:13.000Z","date":"2022-11-18","kind":"purchase","acquired":true,"shares":400,"price":1.7637,"value":705.48,"ownership":{"direct":true},"balance_after":65774,"source":{"system":"sec-edgar","filing":"0001493152-22-033241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000149315222033241/ownership.xml","form_type":"4"}},{"id":2147031,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-03T20:30:46.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-half of the total shares on September 30, 2023 and thereafter the remaining shares vest and become exercisable on September 30, 2024."}],"balance_after":81000,"derivative":{"exercise_price":2.16,"expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001493152-22-027438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000149315222027438/ownership.xml","form_type":"4"}},{"id":2146899,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":78614,"kind":"person","name":"Gilbert Mark John","position":1,"cik":"0001897698","reported_name":"Gilbert Mark John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-03T20:30:42.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on September 30, 2023."}],"balance_after":13750,"derivative":{"exercise_price":2.16,"expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001493152-22-027439","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222027439/ownership.xml","form_type":"4"}},{"id":2147162,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":39271,"kind":"person","name":"O'CALLAGHAN BRIAN","position":1,"cik":"0001415015","reported_name":"O'CALLAGHAN BRIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-03T20:30:26.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on September 30, 2023."}],"balance_after":13750,"derivative":{"exercise_price":2.16,"expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001493152-22-027434","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415015/000149315222027434/ownership.xml","form_type":"4"}},{"id":2147053,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":42337,"kind":"person","name":"Hayes William B","position":1,"cik":"0001320940","reported_name":"Hayes William B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-03T20:30:12.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on September 30, 2023."}],"balance_after":13750,"derivative":{"exercise_price":2.16,"expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001493152-22-027431","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320940/000149315222027431/ownership.xml","form_type":"4"}}],"next_cursor":"2022-10-03T20:30:12.000000Z,2147053"}